TABLE 3.
Race | Metric 1: Surgery/Primary Care
|
Metric 2: Adjuvant Therapy
|
Metric 3: Post-Therapy Surveillance
|
||||||
---|---|---|---|---|---|---|---|---|---|
Matched Cohort
|
Pa | Matched Cohort
|
Pa | Matched Cohort
|
Pa | ||||
No. | Treatment Rate,% | No. | Treatment Rate,% | No. | Treatment Rate,% | ||||
Breast cancer | |||||||||
AI/AN | 206 | 79.1 | .010 | 102 | 61.8 | < .001 | 92 | 64 | .002 |
White | 8052 | 85.7 | 5038 | 82.2 | 4647 | 76.4 | |||
Colon cancer | |||||||||
AI/AN | 194 | 87.1 | .002 | 42 | 45.2 | .001 | 164 | 55.5 | .341 |
White | 2012 | 94.2 | 306 | 72.9 | 1875 | 57.1 | |||
Prostate cancerb | |||||||||
AI/AN | 250 | 39.2 | <.001 | NAc | 10.4 | .756 | 213 | 57.8 | <.001 |
White | 11,119 | 60 | 1264 | 12.1 | 10,131 | 81.4 | |||
Lung cancer | |||||||||
AI/AN | 95 | 26.3 | .025 | NAc | 41.7 | .576 | 129 | 49.6 | .223 |
White | 1128 | 40 | 132 | 30.3 | 1735 | 55 |
Abbreviations: AI/AN, American Indian/Alaskan Native; NA, not available.
P values were based on 1000 bootstrapping iterations.
No sex variable was used for prostate cancer.
Information in this cell is masked to comply with privacy regulations.